NIS-LL: The primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy

European Neurology

Volumn 41, Issue SUPPL. 1, 1999, Pages 8-13

  Bril, Vera ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Clinical trials; Diabetic peripheral neuropathy; Disease progression; Nerve conduction studies; Neuropathy impairment score lower limbs; Quantitative autonomic testing; Quantitative sensory testing

Indexed keywords

RECOMBINANT NERVE GROWTH FACTOR;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEUROPATHY; FOOT ULCER; HUMAN; LEG; NERVE FUNCTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK; SCORING SYSTEM;

EID: 0032981905     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052074     Document Type: Conference Paper

References (32)

1. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH: A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150-154.
2. Consensus Statement of the American Diabetes Association and the American Academy of Neurology: Report and recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes 1988;37:1000-1004.
3. Bril V: Role of electrophysiological studies in diabetic neuropathy. Can J Neurol Sci 1994;21:S81-S12.
4. Bril V, Ellison R, Ngo M, Bergstrom B, Raynard D, Gin H, Roche Neuropathy Study Group: Electrophysiological monitoring in clinical trials. Muscle Nerve 1998;21:1368-1373.
5. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
6. Sima AA, Bril V, Nathaniel V, McEwen TA, Brown M, Lattimer S, Greene DA: Regeneration and repair of myelinated fibers in sural nerve biopsies from patients with diabetic neuropathy treated with sorbinil, an investigational aldose reductase inhibitor. N Engl J Med 1988;319:548-555.
7. Dyck PJ, O'Brien PC: Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care 1989;12:649-652.
8. Arezzo J: The use of electrophysiology for the assessment of diabetic neuropathy. Neurosci Res Commun 1997;21:13-23.
9. Bril V, Kojic J, Ngo M, Clark K: Comparison of a neurothesiometer and vibratron in measuring vibration perception thresholds and relationship to nerve conduction studies. Diabetes Care 1997;20:1360-1362.
10. Consensus Statement: Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Neurology 1992;42:1823-1829.
11. Ewing DJ, Campbell IW, Clarke BF: The natural history of diabetic autonomic neuropathy. Am J Med 1980;49:95-108.
12. Low P, Pfeifer M: Standardization of clinical tests for practice and clinical trials: in Low P (ed): Clinical Autonomic Disorders: Evaluation and Management. Boston, Little, Brown, 1993, pp 287-296.
13. Low P: Pitfalls in autonomic testing: in Low P (ed): Clinical Autonomic Disorders: Evaluation and Management. Boston, Little, Brown, 1993, pp 355-365.
14. Dyck PJ: Detection, characterization, and staging of polyneuropathy: Assessed in diabetics. Muscle Nerve 1988;11:21-32.
15. Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton LJ III, O'Brien PC, Litchy WJ, Windebank AJ, Smith BE, Low PA, Service FJ, Rizza RA, Zimmerman BR: The Rochester Diabetic Neuropathy Study: Design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991;41:799-807.
16. Dyck P: Quantitating severity of neuropathy: in Dyck PK, Thomas PK, Griffin JW, Low PA, Poduslo JF (eds): Peripheral Neuropathy. Philadelphia, Saunders, 1993, pp 685-697.
17. Fedele D, Comi G, Coscelli C, Cucinotta D, Feldman EL, Ghirlanda G, Greene DA, Negrin P, Santeusanio F, The Italian Diabetic Neuropathy Committee: A multicenter study on the prevalence of diabetic neuropathy in Italy. Diabetes Care 1997;20:836-843.
18. Feldman E: Clinical testing in diabetic peripheral neuropathy. Can J Neurol Sci 1994;21:S3-S7.
19. Valk GD, Nauta JJP, Strijers RLM, Bertelsmann FW: Clinical examination versus neurophysiological examination in the diagnosis of diabetic polyneuropathy. Diabetic Med 1992;9:716-721.
20. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC: Variables influencing neuropathic endpoints: The Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995;45:1115-1121.
21. Maser RE, Nielsen VK, Bass EK, Manjoo Q, Dorman JS, Kelsey SF, Becker DJ, Orchard TJ: Measuring diabetic neuropathy: Assessment and comparison of clinical examination and quantitative sensory testing. Diabetes Care 1989;12:270-275.
22. Maser RE, Orchard TJ: Diabetic neuropathy: Its measurement and epidemiologic features. Del Med J 1991;63:85-93.
23. Britland S, Young R, Sharma A, Clarke B: Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes 1990;39:898-908.
24. Ochoa J: Positive sensory symptoms in neuropathy: Mechanism and aspects of treatment: in Asbury A, Thomas P (eds): Peripheral Nerve Disorders. Oxford, Butterworth-Heinemann, 1995, vol 2, pp 44-58.
25. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, Swanson C: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461-465.
26. Thomas PK, Tomlinson DR: Diabetic and hypoglycemic neuropathy: in Dyck PK, Thomas PK, Griffin JW, Low PA, Poduslo JF (eds): Peripheral Neuropathy. Philadelphia, Saunders, 1993, pp 1219-1250.
27. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA, and the NGF Study Group: Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 1998;51:695-702.
28. Kumar S, Fernando DJS, Veves A, Knowles EA, Young MJ, Boulton AJM: Semmes-Weinstein monofilaments: A simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration. Diabetes Res Clin Pract 1991;13:63-68.
29. Olmos PR, Cataland S, O'Dorisio TM, Casey C, Smead WL, Simon SR: The Semmes-Weinstein monofilament as a potential predictor of foot ulceration in patients with non insulin-dependent diabetes. Am J Med Sci 1995;309:76-82.
30. Boulton AJM, Kubrusly DB, Bowker JH, Gadia MT, Quintero DM, Beeker JS, Skyler J, Sosenko M: Impaired vibratory perception and diabetic foot ulceration. Diabetic Med 1986;3:335-337.
31. Rathmann W, Ziegler D, Jahnke M, Haastert B, Gries F: Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabetic Med 1993;10:820-824.
32. Peripheral Nerve Society: Diabetic polyneuropathy in controlled clinical trials: Consensus report of the Peripheral Nerve Society. Ann Neurol 1995;38:478-482.